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Abstract
Background: Late onset Pompe disease (LOPD) is a lysosomal neuromuscular disorder which can progressively
impair the patients’ exercise tolerance, motor and respiratory functions, and quality of life. The available enzyme
replacement therapy (ERT) does not completely counteract disease progression. We investigated the effect of
exercise training alone, or associated with a high-protein diet, on the exercise tolerance, muscle and pulmonary
functions, and quality of life of LOPD patients on long term ERT.
Methods: The patients were asked to participate to a crossover randomized study comprehending a control period (free
diet, no exercise) followed by 2 intervention periods: exercise or exercise + diet, each lasting 26weeks and separated by 13
weeks washout periods. Exercise training included moderate-intensity aerobic exercise on a cycle ergometer, stretching and
balance exercises, strength training. The diet was composed by 25–30% protein, 30–35% carbohydrate and 35–40% fat.
Before and after each period patients were assessed for: exercise tolerance test on a cycle-ergometer, serum muscle
enzymes, pulmonary function tests and SF36 questionnaire for quality of life. Compliance was evaluated by training and
dietary diaries. Patients were contacted weekly by researchers to optimize adherence to treatments.
Results: Thirteen LOPD patients, median age 49 ± 11 years, under chronic ERT (median 6.0 ± 4.0 years) were recruited. Peak
aerobic power (peak pulmonary O2 uptake) decreased after control, whereas it increased after exercise, and more
markedlyafter exercise + diet. Serum levels of lactate dehydrogenase (LDH) significantly decreased after exercise + diet; both
creatine kinase (CK) and LDH levels were significantly reduced after exercise + diet compared to exercise. Pulmonary function
showed no changes after control and exercise, whereas a significant improvement of forced expiratory volume in 1 sec
(FEV1) was observed after exercise + diet. SF36 showed a slight improvement in the “mental component” scale after exercise,
and a significant improvement in “general health” and “vitality” after exercise + diet. The compliance to prescriptions was
higher than 70% for both diet and exercise.
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Conclusions: Exercise tolerance (as evaluated by peak aerobic power) showed a tendency to decrease in LOPD patients on
long term ERT. Exercise training, particularly if combined with high-protein diet, could reverse this decrease and result in an
improvement, which was accompanied by improved quality of life. The association of the two lifestyle interventions resulted
also in a reduction of muscle enzyme levels and improved pulmonary function.
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Introduction
Pompe disease, or glycogen storage disease type II, is a
rare inherited metabolic disorder due to the deficiency
of the enzyme acid alpha glucosidase (GAA), which nor-
mally breaks down the glycogen inside the lysosomes of
various cellular types. The GAA deficiency results into
glycogen accumulation, especially in fibers of skeletal,
respiratory and cardiac muscles; the consequence is a
progressive invalidating disease [1]. In clinical practice
Pompe disease has been differentiated in two main sub-
types: the classic infantile form, rapidly progressive with
cardiac involvement, and the late-onset form (LOPD),
characterized by a slower disease progression and free
from cardiac involvement [2]. In the caucasian popula-
tion the estimated incidence is 1/138.000 for the infant-
ile form and 1/57.000 for LOPD [3]. Exercise
intolerance, defined as the inability to produce/maintain
adequate force or power to accomplish a task, is a key
clinical manifestation of LOPD. Exercise intolerance ap-
pears early in the natural history of the disease and sig-
nificantly impairs the patients’ clinical picture and
quality of life [4–6]. The specific enzyme replacement
therapy (ERT) with recombinant alpha-glucosidase be-
came available in 2006 and showed to be effective on
motor and respiratory functions of LOPD patients [7, 8],
leading to an improved exercise tolerance [5]. However,
different authors observed that the positive effects of
ERT, evident in the first years of treatment, seem to
stabilize or even decline afterwards [9, 10]. Due to the
limitations of ERT, the development and implementa-
tion of ancillary therapeutic approaches are important in
optimizing the care of Pompe patients.
Before the introduction of ERT, the effects of high-
protein diet associated to exercise training in LOPD
have been studied by Slonim et al. [11]; the authors
demonstrated a slowing in the disease progression rate
[11]. In the post-ERT era, however, these life-style inter-
ventions were mostly disregarded in clinical practice. Re-
cently, two studies demonstrated beneficial effects of
aerobic exercise in LOPD patients treated with ERT [12,
13]. To the best of our knowledge, however, no studies
have been conducted on the association of exercise and
a high-protein diet in these patients.
Since the high-protein diet and exercise would act on
different mechanisms, we hypothesized that the
combined effects of the two interventions could be syn-
ergic. Thus, the primary aim of the present study was to
evaluate the effects of an individualized exercise training
program, alone or in association with a high-protein diet,
on exercise tolerance, muscle and pulmonary functions,
and quality of life in LOPD patients chronically treated
with ERT. The secondary aim was to evaluate the patients’
compliance to the proposed intensive life-style interven-
tions, and therefore their feasibility in clinical practice.
Patients and methods
Patients were enrolled by two different centres: the Re-
gional Coordinator Centre for Rare Disease of the Aca-
demic Hospital of Udine, and the Carlo Besta
Neurological Institute of Milan. Main inclusion criteria
were: age ≥ 18 years; diagnosis of LOPD confirmed by
enzymatic test and/or genetic analysis; regular ERT for
at least 2 years. Main exclusion criteria were: presence of
significant cardiovascular diseases (assessed by electro-
cardiogram and echocardiography); wheelchair bound;
24 h ventilator support; pregnancy. Patients who already
performed regular physical activity or followed specific
diets were also excluded.
Study protocol
The study was designed as a partially blinded, randomized,
crossover study. Blinding was applied to the researchers
working at the laboratory assays, instrumental testing and
data analysis. Following a control period (free diet, no ex-
ercise training), participants were randomly assigned to a
sequence of two treatment periods: exercise alone and ex-
ercise + dietEach period lasted 26 weeks and was followed
by a 13-week wash-out (free diet, no exercise training). Pa-
tients continued ERT during the entire study period, at
the usual dosage (20mg/kg every 2 weeks).
The study was approved by the ethical committees of
the Friuli Venezia Giulia region and of the Carlo Besta
Neurological Institute of Milan. All patients signed an
informed consent before entering the study.
Exercise training
Exercise training was prescribed after an initial evalu-
ation of exercise tolerance and muscular strength carried
out in the exercise physiology laboratories (Department
of Medicine, University of Udine, Institute of Bioimaging
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and Molecular Physiology, National Research Council,
Milan) participating to the study. Patients were carefully
instructed about the training protocol during the initial
visits at the exercise physiology laboratories. Training,
conducted at home, was personalized for each patient
and comprehended 4 sessions/week, 1 h/session. Each
session included: 1) Warm-up exercises. 2) Stretching
and balance exercises (10–15 min). 3) Strenght training
at very moderate loads involving the main muscle
groups of the upper (shoulder adductions and abduc-
tions in the frontal plane, bicep curls in the sagittal
plane, chest press in the sagittal plane and back rows in
the sagittal plane), lower limbs (leg adductions and ab-
ductions in the frontal plane and back squats) and of the
trunk (spinal rotations in the transverse plane), carried
out by utilizing elastic bands (THERA-BAND, Akron,
Ohio, USA) (15 min). During the initial evaluation of the
patients the length of the elastic band was set corre-
sponding to a “very moderate” resistance, according to
the manufacturer’s instructions. Three series of 10 repe-
titions were performed for each movement. The resist-
ance of the bands and the number of repetitions were
kept constant throughout the study. 4) Moderate-
intensity aerobic exercise on a cycle ergometer, carried
out at about 60% of the patient’s maximal heart rate
(HR) determined during the preliminary incremental test
(see below) (30–40min). A cycle ergometer with a HR-
meter (Ergo bike, Cardio Pro, Daum Electronic, Germany)
was shipped to each patient’s domicile for the training pe-
riods. The HR-meter allowed the downloading of data on
a personal computer. Since aerobic training intensity was
targeted to a specific HR value, and not to a specific work
rate, the adjustment of training intensity to increases or
decreases of exercise tolerance was automatic, without the
need for interim evaluations with incremental exercise
tests during each period of the study.
Dietary treatment
Before receiving the dietary prescription, the patients
underwent a complete nutritional and dietary assess-
ment at the Academic Hospital of Udine or at the Inter-
national Center for the Assessment of Nutritional Status
(ICANS), University of Milan.
The patients were asked to follow a personalized high-
protein diet, composed by 25–30% protein, 30–35%
carbohydrate and 35–40% fat. Caloric requirements were
calculated by sex, age, body weight and height according
to the Harris-Benedict formula [14], sedentary physical
activity level (PAL = 1,45 (SINU-Società Italiana di
Nutrizione Umana. LARN- revision 2014), and nutri-
tional status at baseline.
Daily protein amount was distributed in 6 meals: 20%
at breakfast, 25% at lunch, 25% at dinner and the
remaining 30% in three snacks (10% during the morning,
10% during the afternoon and 10% in the last snack after
dinner). A neutral or flavored powder was used to create
ready-to-drink products rich in protein for breakfast in
patients who did not like salty breakfast. Only dietary
protein sources were used in other meals (animal pro-
teins 49 ± 11%, vegetable proteins 27 ± 9%).
Efficacy assessments
The following assessments were performed before and
after each intervention period (control period included).
Anthropometrics and body composition measurements
The anthropometric and body composition measure-
ments included weight, height, body mass index (BMI,
kg/m2), waist circumference.
Bioelectrical impedance (BIA)
Total body water, intracellular water, and extracellular
water (ECW, L) were measured by the tetrapolar 8-point
tactile electrode system using an impedance (InBody
S10, Biospace, Seoul, Korea) at 1, 5, 50, 250, 500, and
1000 kHz. BIA was performed with patients fasting for
at least 4 h, without having exercised in the last 12 h,
without having drunk water in the last hour.
Functional evaluation of exercise tolerance
Experiments were conducted under medical supervision,
and patients were continuously monitored by 12-lead
electrocardiography (ECG). A mechanically braked cycle
ergometer (Monark Ergomedic 839E) was utilized. Ped-
alling frequency was digitally displayed to the subjects,
who were asked to keep a constant cadence throughout
the test, between 60 and 70 rpm. Each patient had
chosen his preferred cadence during practice trials, and
this cadence was maintained during each repetition. Pa-
tients were allowed time to gain familiarity with the re-
searchers and the experimental set-up, were carefully
instructed about the procedures and were familiarized
with the protocol using short practice runs before start-
ing the study.
A specific functional evaluation protocol was utilized as
previously described [6]. The patients performed a low-
intensity constant work rate (CWR) exercise for 8min or
until voluntary exhaustion, identified as the inability to
maintain the desired cadence, despite verbal encourage-
ment. In the patients who completed the CWR exercise,
the test was immediately followed by an incremental exer-
cise up to voluntary exhaustion. During the incremental
exercise, work rate was increased by 5–10W every mi-
nute. Pulmonary ventilation (V̇E), tidal volume (VT), re-
spiratory frequency (fR), O2 uptake (V̇O2) and CO2
output (V̇CO2) were determined on a breath-by-breath
basis by means of a metabolic unit (Quark b2, Cosmed,
Italy). Expiratory flow measurements were performed by a
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turbine flow meter calibrated before each experiment by a
3 L syringe at three different flow rates. Calibration of O2
and CO2 analysers was performed before each experiment
by utilizing gas mixtures of known composition. The gas
exchange ratio (R) was calculated as V̇CO2/ V̇O2. Arterial
oxygen saturation (SpO2) was determined at the earlobe
by pulse-oximetry (Oximeter Xpod, 3012LP, Cosmed,
Italy).
Heart rate was determined by ECG.
For all variable’s values determined at voluntary ex-
haustion were considered “peak” values. The time to ex-
haustion was also determined.
Other parameters of clinical outcome
Muscle force of the right lower limb (knee angle at 110°)
and right upper limb (elbow angle at 90°) were measured
during an isometric maximal voluntary contraction
(MVC), during both flexion and extension, using a
TSD121C isometric dynamometer (Biopac Systems Inc.,
Santa Barbara, CA, USA). Force analog output was sam-
pled at a frequency of 1 kHz, and was acquired with the
BIOPAC System MP100 (Biopac Systems Inc., Santa
Barbara, CA, USA) using AcqKnowledge software ver-
sion 3.7.2. Peak values of every trial were identified and
retained for data analysis.
Serum muscular enzymes (creatinekinase CK, lactate
dehydrogenase LDH, alanine transaminase ALT, and as-
partate transaminase AST), and other hematologic pa-
rameters (glucose, hemoglobin, lipid profile, albumine,
creatinine) were measured by standard procedures.
Pulmonary function tests included a standard spirom-
etry with the evaluation of the vital capacity (VC) and
the forced expiratory volume in 1 sec (FEV1), reported
as % of normal values [15].
Walking distance during the 6-min walking test
(6MWT) was evaluated according to the American
Thoracic Society guidelines [16].
Modified Walton Scale scores were assessed according
to Slonim et al. 2006 [17].
Quality of life
Quality of life was assessed using the validated, standard-
ized Italian version of the SF36 questionnaire [18]. The
36 items were divided into eight concepts plus one
health comparison question. The eight concepts to be
scored were: Physical Functioning, Role-Physical, RoleE-
motional, Social Functioning, Bodily Pain, Mental
Health, Vitality, General Health Perceptions, and Change
in Health. The raw scale scores were computed by sum-
ming across items within each concept. The raw scores
were transformed to a 0–100 scale using the formula = [(
actual raw score - lowest possible raw score)/ possible
raw score rangel • 100] and then normalized to a Z-
score. The physical and mental component summary
measures were also computed and transformed to
norm-based scores (mean 50, standard deviation 10)
using the mean, standard deviation, and scoring coeffi-
cients from the US general population [19]. Both for
combined scales and summary measures, higher scores
indicate higher levels of physical functioning or psycho-
logical well-being.
Compliance assessment
Patients’ compliance to the exercise training was assessed
by analysis of the 7 days training diaries completed during
the interventions period, and by the analysis of the data of
the HR-meter of the cycle-ergometers. Three-days
weighted-dietary diaries, completed every month during
all the study periods, were used to evaluate food intake,
and to assess dietary habits. Each day of the food record
was assessed for completeness by a trained dietician, and
then coded and analyzed using the WinFood® 3.0 software.
During the intervention periods weekly phone-calls or e-
mails were utilized by the research staff to optimize adher-
ence to treatments.
Statistical analysis
Descriptive statistics were performed on categorical and
numerical variables. Frequency distributions were used
for categorical variables. For numerical variables we con-
sidered median, interquartile range, minimum and max-
imum values. Due to the low sample size, analyses were
conducted using non parametric tests. After checking
for the absence of a carry-over effect (two-stage Grizzle
model and graphical assessment), pre and post interven-
tion results were compared by Wilcoxon rank sum test
for paired data.
Exercise and exercise+diet period were also compared
by applying the Wilcoxon signed rank sum test for
paired data to the difference between the two periods for
the percentage before - after difference data.
All statistical analyses were performed using SAS© soft-
ware, version 9.4 (SAS institute, Inc., Cary, NC, USA) and
R software, version 3.4.2. The significance level was set at
p < 0.05. In some specified cases, considering the relatively
small population included in the study, data of interest
with a p-value < 0.10 were reported.
Results
Thirteen LOPD patients were enrolled, two couples were
brothers (UD02- UD04; MI05-MI06), whereas the other
patients were unrelated. The patients general character-
istics at study entry are summarized in Table 1; median
age at the beginning of the study was 49.0 ± 11.0 years,
all were on long term ERT (median treatment duration
6.0 ± 4.0 years). The disease severity was variable, and
Walton Scale scores ranged from 0 (all activities normal)
to 6 (walking only with callipers); 8 patients were on
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non-invasive nocturnal ventilation (NIV). Regarding
genotype, all participants but one (patient UD07) were
compound heterozygous for the common LOPD muta-
tion c.-32-13 T > G.
Two patients (UD04 and MI04) dropped out of the
study, for personal reasons, after the control period, an-
other one (UD05) completed the control and the exercise
periods but not the exercise + diet period. Four patients
(UD06, UD07, MI05, MI06) were enrolled late during
the study, and could not perform the control period.
Therefore, data before and after the control period were
available for 9 patients, data before and after exercise
were available for 11 patients, and data before and after
exercise + diet were available for 10 patients.
Three out of 10 patients who completed the exercise +
diet period were overweight at baseline (UD02, MI03,
MI05), and therefore received a hypocaloric diet with a
caloric deficit corresponding to 20% of their daily energy
expenditure, whereas the other patients received a nor-
mocaloric diet. The exercise and diet interventions, per-
formed at home, were in general well tolerated.
The two-stage Grizzle model and the graphical assess-
ment excluded a carry-over effect between the interven-
tion periods. Comparison of parameters obtained before
and after each period showed the following results:
Anthropometrics and body composition measurements
When considering all patients, BMI (kg/m2) significantly
decreased after the exercise + diet period (p < 0.05), going
from a median value of 21.7 ± 6.9 before to 21.3 ± 5.7
after the intervention. No differences occurred in body
composition, as measured by bioelectrical impedance,
across the study.
Functional evaluation of exercise tolerance
Peak values of the investigated variables are presented in
Table 2. Both when expressed as L.min− 1 and after the
normalization for body mass (mL.kg-1.min− 1) V̇O2 peak
values (maximal aerobic power) decreased after control
(p = 0.004), whereas they increased after exercise (p =
0.05) and showed a more significant improvement after
exercise + diet (p = 0.009). Also peak work rate and the
time to exhaustion presented similar patterns of change
compared to those observed for V̇O2 peak, although a
statistically significant difference was not always reached,
presumably as a consequence of data scattering. No ar-
terial desaturation was observed in any of the experi-
mental conditions.
No significant differences in the peak values of ventila-
tory variables (V̇E, VT, fR, V̇CO2) were observed across
conditions. The same applies to R peak values. In all
conditions mean R peak values were higher than 1.0,
suggesting that the exercise was indeed, on average, sub-
stantially maximal for the patients. HR peak values were,
in all conditions, substantially lower than the age-
predicted “normal” values, suggesting that the exercise,
although exhausting (see R peak) did not represent a
maximal burden for the cardiovascular system, thereby
suggesting a mainly “peripheral” (locomotor muscles)
limitation to exercise tolerance.
Other parameters of clinical outcome
Results of this section are presented in Table 3.
No significant differences were found in muscle
strength, during both flexion and extension exercises of
the lower and upper limbs, in after vs. before all experi-
mental conditions.
Table 1 General characteristics of patients
Patient ID Gender Age at study entry Age at diagnosis Years on ERT Walton scale score BMI before diet Ventilatory support
UD01 M 19 3 9 0 20.7 no
UD02 M 48 41 6 0 30.5 no
UD03 F 49 29 6 3 17.5 no
UD04 M 55 45 9 3 NA NIV
UD05 F 46 25 9 6 NA NIV
UD06 F 42 29 9 3 23.7 NIV
UD07 F 45 16 10 6 16.4 NIV
MI01 F 69 66 3 3 21 no
MI02 M 71 67 4 3 19.6 NIV
MI03 F 36 32 5 3 27.8 no
MI04 F 56 37 6 3 NA NIV
MI05 F 59 54 5 3 28.4 NIV
MI06 M 51 45 6 2 22.3 NIV
Median ± IQR 49.0 ± 11.0 37.0 ± 16.0 6.0 ± 4.0 21.65 ± 6.9
NIV nocturnal non invasive ventilation
NA not applicable
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Serum muscle enzymes showed a significant decrease
of LDH after the exercise + diet period.
Comparing exercise and exercise + diet periods by the
Wilcoxon signed rank sum test for paired data, statistically
significant differences were found for CK and LDH be-
tween the two periods for the % difference (before - after),
that corresponds to a significant reduction in CK and
LDH levels (p = 0.03 and p = 0.04) after the exercise + diet
period, compared to the after exercise period data.
No differences were found in blood glucose,
hemoglobin, lipid profile, albumin, creatinine levels
throughout the study.
No significant differences were found for the distance
walked during the 6MWT.
The Walton scale score of each patient did not change
during the study.
Pulmonary function tests showed a trend toward im-
provement in VC% (p = 0.06) and a significant increase
in FEV1% (p = 0.04) after the exercise + diet period,
whereas no changes were observed for these variables in
the other experimental conditions.
Quality of life
No differences were found after the control period, while
after the exercise period there was a trend toward im-
provement in the mental component scale (p = 0.07), and
after the exercise + diet period improvements in several
thematic areas were described: mental health (p = 0.07),
mental component scale (p = 0.09); the observed differ-
ences reached statistical significance in general health
(p = 0.03), and vitality (p = 0.03) (Table 4).
Compliance
From the analysis of the training diaries and the HR-
meters of the cycle-ergometers, the level of adherence to
exercise prescriptions were elevated: for the warm up
period the percentage of adherence to the prescribed ex-
ercise sessions was 69%, for strength training 61%, for
cycling 74%, for stretching 69%. These percentages were
not significantly different between the exercise and the
exercise + diet periods.
The analysis of the dietary diaries showed a significant
modification of the habitual diet during the exercise +
Table 2 Peak values of the main variables determined during incremental exercise
Control Exercise Exercise + Diet
Before After p-value Before After p-value Before After p-value
VO2 peak (ml/min/kg) 17,77 ± 6,96 15,88 ± 4,78 0,039 19,24 ± 18,39 21,57 ± 13,26 0,053 20,22 ± 7,27 22,22 ± 4,56 0,009
VO2 peak (l/min) 1,19 ± 1,43 1,16 ± 0,77 0,023 1,23 ± 1,16 1,37 ± 0,62 0,019 1,21 ± 0,56 1,38 ± 0,44 0,027
HR peak (bpm) 143 ± 18 130 ± 14 0,16 137 ± 41 143 ± 37 0,865 146,5 ± 30 148 ± 44 0,113
HR peak (% pred) 85 ± 2 70 ± 20 0,042 82 ± 25,5 80 ± 14,5 0,905 84,5 ± 5,75 90 ± 16,25 0,059
Work rate peak (watt) 55 ± 35 45 ± 40 0,375 75 ± 80 75 ± 70 0,023 62,5 ± 55 72,5 ± 55 0,093
VCO2 peak (l/min) 1,37 ± 0,89 1,31 ± 0,95 0,195 1,34 ± 1,25 1,46 ± 0,93 0,637 1,52 ± 0,60 1,64 ± 0,76 0,039
VE peak (l/min) 45,02 ± 25,14 40,59 ± 27,39 0,195 42,48 ± 45,77 41,62 ± 36,56 0,464 47,98 ± 20,42 49,62 ± 24,29 0,064
R peak 1,06 ± 0,1 1,07 ± 0,12 0,234 1,1 ± 0,12 1 ± 0,16 0,224 1,08 ± 0,21 1,13 ± 0,16 0,75
time to exhaustion (min) 14 ± 8 13 ± 4 0,142 15 ± 15 16 ± 8 0,014 13 ± 6,25 16,5 ± 4,5 0,124
Data are expressed as median ± interquartile range before and after each intervention period
VO2 oxygen uptake, HR heart rate, VCO2 CO2 output, VE pulmonary ventilation, R gas exchange ratio
Table 3 Other parameters of clinical outcome
Control Exercise Exercise + Diet
Before After p-value Before After p-value Before After p-value
Arms Extensors (N) 105,13 ± 46,27 107 ± 103,21 0,8125 46,11 ± 84,42 55,36 ± 76,91 0,3125 96,86 ± 96,02 87,4 ± 101,1 0,4609
Arms Flexors (N) 104,48 ± 106,84 123,38 ± 80,9 0,5469 74,8 ± 79,88 64,74 ± 59,54 0,25 97,65 ± 79,4 89,03 ± 78,78 0,1953
Legs Extensors (N) 164,23 ± 111,47 185,95 ± 120,07 0,5469 136,62 ± 186,13 148,5 ± 81,51 0,3125 179 ± 199,61 152,86 ± 248,1 0,9453
Legs Flexors (N) 120,87 ± 85,22 94,88 ± 74,49 0,9375 80,62 ± 79,91 55,5 ± 47,26 0,2109 67,7 ± 33,84 79,73 ± 60,5 0,3125
CK (U/L) 280 ± 257 279 ± 284 0,2383 258 ± 262 371 ± 213 0,4131 272,5 ± 218 255 ± 104 0,1406
LDH (U/L) 322 ± 209 325 ± 215 0,1367 320 ± 218 320 ± 257 0,2012 303 ± 278 261,5 ± 240 0,0469
6MWT (m) 404 ± 93 412 ± 127 0,4258 425 ± 151 420 ± 152 0,166 416,8 ± 129 409 ± 119,2 1
VC (%) 70 ± 33 71 ± 31 0,1797 71 ± 42 71 ± 48,5 0,9844 75 ± 42 89,5 ± 44 0,0625
FEV1 (%) 70 ± 33 71 ± 38 0,3789 71 ± 42 72,4 ± 39,5 0,4844 66,5 ± 53 85 ± 49 0,0391
Data are expressed as median ± interquartile range before and after each intervention period
6MWT maximum walking distance measured by the 6min walking test
VC vital capacity, FEV1 forced expiratory volume in 1 s
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diet period, with an increase in protein intake and a de-
crease in carbohydrate intake (Fig. 1). The percentage of
calories introduced with proteins was 96%(median value)
of those prescribed, and 145% of those introduced with
the habitual diet (p < 0.05).
Discussion
The main aim of the present study was to evaluate, in LOPD
patients long term treated with ERT, the effects of exercise
alone (exercise) or combined to a high-protein diet (exer-
cise + diet) on indices of exercise tolerance, motor and re-
spiratory functions and quality of life. A control period of no
intervention was also present in the protocol.
Interestingly, we observed that the V̇O2 peak de-
creased in control, whereas it increased in exercise and
more significantly so in exercise + diet. V̇O2 peak, a close
estimate of maximal aerobic power, is traditionally con-
sidered an index evaluating the maximal performance of
the integrated respiratory, cardiovascular and muscular
factors governing oxidative metabolism during exercise,
in other words the maximal flux of O2 from ambient air
to the mitochondria of skeletal muscles [20]. In more
functional terms, V̇O2 peak estimates the maximal
power which can be sustained by oxidative metabolism,
and therefore the maximal power which can be sus-
tained for a relatively long period of time (several mi-
nutes) without incurring in fatigue. Besides its obvious
relationship with exercise tolerance, and therefore with
the patients’ quality of life, it has been demonstrated that
in different pathological conditions (such as cardiovascu-
lar or respiratory diseases) V̇O2 peak also possesses a
strong prognostic relevance [21]. It is noteworthy that
during the 6-month period of control V̇O2 peak showed
a significant decrease. This seems to be compatible with
the clinical observation that many patients long term
treated with ERT show disease progression despite the
therapy [9, 10]. Our data suggest that regular exercise, in
particular in association with a high-protein diet, can
counteract the progressive loss of V̇O2 peak.
Rather surprisingly, the observed changes in V̇O2 peak
were not associated with changes in the results obtained
during the 6MWT, which did not change following any
experimental conditions. This discrepancy further sup-
ports data from a previous study by our group [6], sug-
gesting that in LOPD patients V̇O2 peak is a more
sensitive parameter than the distance walked during
6MWT in the assessment of the patients’ exercise toler-
ance. It is also possible that the 6MWT performance is
more related that the V̇O2 peak to the strength of the
proximal muscle of the legs. Indeed, no changes in
muscle strength were observed in all experimental con-
ditions. This is presumably attributable to the very mod-
erate resistance to movements imposed by the elastic
bands. The very moderate resistance was chosen to
avoid risks of inducing muscle damage.
The results in terms of V̇O2 peak are compatible with
those found in relation to the quality of life evaluation,
which showed a slight amelioration after exercise, and
significant improvements for different aspects after exer-
cise + diet. Interestingly, the association of the high-
protein diet with exercise improved also other clinically
relevant outcomes, such as the blood levels of muscular
enzymes (which showed a decrease, especially of LDH),
and variables of respiratory function (VC and FEV1); the
improvements of blood levels of muscular enzymes and
of spirometry variables were not observed after exercise
alone. Based on these results, it can be hypothesized that
high protein diet has an effect in restoring not only skel-
etal muscle function but also respiratory muscles.
The rationale to combine exercise + diet in LOPD pa-
tients comes from cell pathology. The damage of muscle
fibers in these patients is indeed not only related to
Table 4 Quality of life before and after exercise and exercise + diet periods
Exercise Exercise + Diet
Median score Before Median Intra personal variation p-value Median score Before Median Intra personal variation p-value
PF 25 0.00 0.812 45 5.00 0.375
RP 50 0.00 0.406 25 0.00 0.375
BP 52 0.00 0.562 52 0.00 0.437
GH 45 −5.00 0.578 30 5.00 0.031
VT 40 0.00 0.25 40 10.00 0.031
SF 75 12.50 0.156 50 0.00 0.375
RE 100 0.00 0.75 66.67 0.00 0.625
MH 72 4.00 0.152 56 12.00 0.070
PCS 34.25 0.26 0.652 33.61 1.83 0.25
MCS 53.92 3.06 0.074 41.15 4.29 0.097
PF Physical Functioning, RP Role-Physical, BP Bodily Pain, GH General Health, VT Vitality, SF Social Functioning, RE Role Emotional, MH Mental Health, PCS Physical
Component Scale, MCS Mental Component Scale
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glycogen accumulation, but also to secondary derange-
ments such as increased proteolysis and aberrant au-
tophagy [22]. Exercise and diet could counteract this
process, acting on different mechanisms. In fact, in
muscle fibers aerobic exercise can modify energy metab-
olism, increasing the use of fatty acids as an alternative
source of energy, thus reducing proteolysis, autophagy
and muscle damage [17]. Moreover, exercise training can
counteract the general deconditioning typical of chronic
diseases, as well as the chronic inflammatory condition as-
sociated with inactivity [23]. On the other hand, the high-
protein low-carbohydrate diet can reduce glycogen depos-
ition in muscle fibers and increase intracellular protein
synthesis, thereby reducing glycogen accumulation, prote-
olysis, muscle autophagy and damage [17, 24].
Before the approval of ERT, many clinicians prescribed
diet and exercise to LOPD patients, based on data by
Slonim et al. obtained in a 10 years retrospective study
on 34 patients with LOPD, treated with the so-called
NET (nutrition and exercise therapy) [11]. The nutri-
tional approach adopted by Slonim et al. consisted of
25–30% protein, 30–35% carbohydrate, and 35–40% fat,
which is the same approach used in the present study.
Patients on NET also took supplements of the aminoa-
cid L-alanine, which was not used in the present re-
search since further studies failed to demonstrate the
clinical efficacy of this supplementation [25]. In NET the
exercise intervention consisted of a daily treadmill pro-
gram for 45–50min, followed by aerobic upper-body ex-
ercise for 10–15 min. In the present study we chose to
use exercise on a cycle-ergometer to allow the participa-
tion of patients who had ambulatory difficulties and pro-
posed only for 4 sessions a week in order to make the
intervention more compatible with the patients’ everyday
life and to increase their compliance. The rate of clinical
deterioration (as estimated by the Walton Scale) during
NET was compared with the rate of deterioration ob-
served before starting NET: the data showed that the
more compliant patients responded far better than those
who became less active and did not follow the diet [11].
No differences were found for the Walton scale score in
our study, probably since the control and intervention
periods of 6 months were too short to observe modifica-
tions on this scale.
After the advent of ERT for Pompe disease, only a few
studies investigated the effects of exercise on ERT-
treated patients [12, 13, 26] and, to the best of our
knowledge, no studies investigated the effects of a high-
protein diet associated with exercise in these patients.
The advantages of associating physical exercise with
ERT were first demonstrated in a study performed in
the mouse model of Pompe disease, in which the ani-
mals underwent treadmill training and showed improved
aerobic capacity, strength and motor functions [27]. In
2011 Terzis et al. [12] reported the effects of a 20-week
exercise training in 5 LOPD patients receiving ERT. The
prescribed exercise consisted in 3 sessions a week, in-
cluding 30 min of cycling, stretching and resistance
training. Significant increases in muscular strength and
in the distance walked during the 6MWT were observed
Fig. 1 Diet composition before and after exercise + diet period. **p < 0.05. CHO: carbohydrate
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after training [12]. More recently, Van der Berg et al.
[13] performed a larger study, including 25 patients with
LOPD who performed 12 weeks of exercise training
while continuing their ERT infusions. The prescribed ex-
ercise consisted in 3 sessions a week of training combin-
ing aerobic, resistance and core stability exercises,
utilizing a cycle ergometer and other gym instruments
such as chest press, biceps curl, leg press and leg curl.
After training V̇O2 peak and maximum workload cap-
acity improved significantly, while pulmonary function
(VC) did not change. Increases in strength of the hip
flexors and the shoulder abductors were also observed.
The distance walked during the 6MWT increased by 6%.
Two patients experienced significant increases of CK but
the exercise was generally well tolerated [13]. Compared
to the study of Van der Berg et al. [13] our population of
LOPD patients seems to be more severely affected at
baseline, with 11 out of 14 patients having walking diffi-
culties; this might explain the lack of significant changes
in the 6MWT and in muscle strength in our patients
after exercise. Overall, a comparison with previous stud-
ies carried out prescribing exercise in patients receiving
chronic ERT seems to confirm the concept that exercise
alone does not ameliorate blood levels of muscle en-
zymes (CK actually tends to increase) and variables of
pulmonary function, which, can ameliorate when an
high-protein diet is introduced in addition to exercise.
(see Slonim et al. [11] and the present study).
The lack of previous studies on nutritional interven-
tions in LOPD patients receiving chronic ERT could be
linked to the difficulty of guaranteeing compliance to
high-protein diets, as a consequence of the lower palat-
ability of many high-protein foods compared to those
with high carbohydrate content, or of the higher satiety
power of proteins, which may lead to a reduction in food
intake [28]. A review [29] published in the pre-ERT era,
dealing with LOPD patients on high-protein diets, re-
ported that only 25% of patients showed improvements
in muscle or respiratory function. However, the compli-
ance to the diet in most of the studies mentioned in that
review was very poor. The authors attributed the prob-
lems of compliance to the large amount of prescribed
proteins and to the associated perceived risk of weight
gain [29]. Conversely, in our study we obtained a very
high compliance to the prescribed diet, presumably as a
consequence of the personalization of the food compos-
ition of the diet carried out by experienced nutritionists
who took in consideration the patients’ preferences and
habits. A strict contact between patients and dieticians
was assured throughout the exercise + diet intervention.
The risk of weight gain was not confirmed by our data,
which on the contrary showed a significant reduction of
BMI during exercise + diet, even in patients following
normocaloric diets. A high-protein diet, as the one
prescribed in the present study, should be carefully pre-
scribed and monitored in underweight patients, and the
different dietary sources of proteins should be wisely
chosen, assuring great variety between meat, fish, eggs,
dairy products and vegetables proteins (as beans or
nuts). Some experimental and observational human
studies have suggested that a highprotein intake may in-
crease kidney diseases, but only a few randomized trials
with an observation time longer than 6months have
been carried out on this topic; most of these studies,
moreover, were conducted in patients with pre-existing
diseases that predispose them to the development of kid-
ney diseases [30]. In any case, a screening for kidney dis-
eases and a strict monitoring of creatinine and urinary
parameters should be considered before and during a
long-term treatment with a high-protein diet. Of note,
no changes in creatinine plasma values were observed
throughout the study.
The present study presents several limitations. In par-
ticular, the total number of patients who completed the
3 periods was relatively limited. This could be explained,
at least in part, by considering the rarity of the disease
and the length of the study (overall duration 24months).
Despite the relatively low number of patients, however,
the obtained data showed statistically significant differ-
ences in some of the main variables of interest, following
some of the proposed interventions. This could be at-
tributed to the elevated compliance by the patients to
the proposed life style interventions, facilitated by the
constant motivational contacts between researchers and
patients. Eight out of the 10 patients who completed the
exercise + diet period were keen on following the same
prescriptions also after the end of the study. Long term
follow-up data of these patients are necessary to see if
the compliance and the beneficial effects of the interven-
tions will be maintained.
Conclusion
In this study a high-protein diet associated with moderate-
intensity aerobic exercise improved exercise tolerance,
muscle enzymes, pulmonary function and quality of life of
LOPD patients chronically treated with ERT. Since LOPD in
advanced stages causes significant disability and ERT efficacy
seems to decrease during long-term treatment, moderate-
intensity aerobic exercise training in association with a high-
protein diet might be promoted as part of the standard care
of these patients, in order to reduce their demand for assist-
ance and improve their quality of life.
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